News | February 08, 2009

Modified Angioplasty Procedure May Reduce Heart Damage

February 9, 2009 - Emory University cardiologists are testing a modification of angioplasty known as postconditioning, designed to reduce permanent damage to the heart muscle after a heart attack.

The rush of blood back into the heart after a blood vessel is reopened during angioplasty can produce “reperfusion injury,” caused by biochemical changes in the heart muscle. The modified procedure inflates and deflates the balloon several times in a precisely controlled way, so that blood back flows into the heart gradually and thereby reduces the risk of reperfusion injury.

"This study could help refine a common, well-established procedure performed on thousands of patients every year," said principal investigator Habib Samady, M.D., associate professor of medicine (cardiology) at Emory University School of Medicine. "Without involving any additional drugs or devices, it may be possible to reduce damage to the heart muscle in a very straightforward way."

The Emory study — one of the first to test postconditioning in the U.S. — aims to determine whether postconditioning can benefit patients undergoing angioplasty and if so, to define how.

Post-conditioning has been tested in France, Israel, Denmark and Canada. In addition, a 2007 retrospective study of heart attack patients in Massachusetts who, without prior planning by doctors, required several balloon inflations showed that these patients had less damage to their hearts.

The Emory investigators will assess the degree of heart muscle damage in groups of patients treated with standard angioplasty versus those treated with a modified procedure using MRI and echocardiography.

The Emory study began in September 2008 and doctors have already treated several patients with the modified angioplasty procedure, with a total of 40 participants planned.

For more information: www.whsc.emory.edu


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now